CLORAZEPATE DIPOTASSIUM (klor-az'e-pate) 
  Novoclopate  ,  Tranxene, Tranxene-SD Classifications: anxiolytic; sedative-hypnotic; anticonvulsant; benzodiazepine;  Therapeutic: antianxiety agent; sedative-hypnotic; anticonvulsant Prototype: Lorazepam Pregnancy Category: D Controlled Substance: Schedule IV
  |  
 
 
 
 
 Availability
 
 3.75 mg, 7.5 mg, 15 mg capsules and tablets; 11.25 mg, 22.5 mg long acting tablets
 
 Action
 
 Anxiolytic benzodiazepine with moderately rapid onset of action and a long half-life. Benzodiazepines exert their effects 
 through enhancement of GABA-benzodiazepine receptor complex. GABA is an inhibitory neurotransmitter. Clorazepate has depressant 
 effects on the CNS, thus controlling anxiety associated with stress and also resulting in sedative effects. 
 
 
 Therapeutic Effect
 
 Effective in controlling anxiety and withdrawal symptoms of alcohol.
 
 Uses
 
 Management of anxiety disorders, short-term relief of anxiety symptoms, as adjunct in management of partial seizures, and 
 symptomatic relief of acute alcohol withdrawal. 
 
 
 Contraindications
 
 Hypersensitivity to clorazepate and other benzodiazepines; acute narrow-angle glaucoma; depressive neuroses; pulmonary disease, 
 COPD; psychotic reactions, drug abusers. Safe use during pregnancy (category D), lactation, and in children <9 y not established. 
 
 
 Cautious Use
 
 Older adults; debilitated patients; hepatic disease; kidney disease; Parkinson's disease; neuromuscular disease; seizure 
 disorders; bipolar disorder, mania, history of suicidal ideation. 
 
 
 Route & Dosage
 
  
  
 Anxiety Adult: PO 15 mg/d h.s., may increase to 1560 mg/d in divided doses (max: 60 mg/d)
  Acute Alcohol Withdrawal Adult: PO 30 mg followed by 3060 mg in divided doses (max: 90 mg/d), taper by 15 mg/d over 4 d to 7.515 mg/d until patient 
 is stable
  Partial Seizures Adult: PO 7.5 mg t.i.d. Child (912 y):  PO  3.757.5 mg b.i.d., may increase by no more than 3.75 mg/wk (max: 60 mg/d)
  |  
 
 
 
 
 
Administration
Oral 
 - Give with food to minimize gastric distress. Give antacid no less than 1 h before or 1 h after drug ingestion.
  
 - Ensure that sustained-release form of drug is not chewed or crushed. It must be swallowed whole.
  
 - Taper drug dose gradually over several days when drug is to be discontinued. Abrupt termination may lead to memory impairment, 
 severe GI symptoms, muscle pain, restlessness, irritability, fatigue, insomnia. 
 
  
 - Store in light-resistant container at 15°30° C (59°86° F) unless otherwise specified.
  
 
 
 Adverse Effects (≥1%)
 Body as a Whole: Allergic reactions. 
CV: Hypotension. 
GI: GI disturbances, abnormal liver function tests, xerostomia. 
Hematologic: Decreased Hct, blood dyscrasias. 
CNS: Drowsiness, ataxia, dizziness, headache, paradoxical excitement, mental confusion, 
insomnia. 
Special Senses: Diplopia, blurred vision. 
 
Interactions
Drug: Alcohol and other 
cns depressants compound CNS depression; clorazepate increases effects of 
cimetidine, disulfiram, causing excessive sedation. 
Herbal: Ginkgo may decrease anticonvulsant effectiveness. 
 
Pharmacokinetics
Absorption: Decarboxylated in stomach; absorbed as active metabolite, desmethyldiazepam. 
Peak: 1 h. 
Duration: 24 h. 
Distribution: Crosses placenta; distributed into breast milk. 
Metabolism: In liver to 
oxazepam. 
Elimination: Primarily in urine. 
Half-Life: 30200 h. 
 
Nursing Implications
 
 Assessment & Drug Effects
 
  
 - Drowsiness, a common side effect, is more likely to occur at initiation of therapy and with dose increments on successive 
 days. 
 
  
 - Lab tests: Periodic blood counts and tests of liver and kidney function should be performed throughout therapy.
  
 - Monitor patient with history of cardiovascular disease in early therapy for drug-induced responses. If systolic BP drops 
 more than 20 mm Hg or if there is a sudden increase in pulse rate, withhold drug and notify physician. 
 
  
 
 
 Patient & Family Education
 
  
 - Take drug as prescribed and do not change dose or abruptly stop taking the drug without physician's approval.
  
 - Do not self-dose with OTC drugs (cold remedies, sleep medications, antacids) without consulting physician.
  
 - Avoid driving and other potentially hazardous activities until reaction to drug is known.
  
 - Do not use alcohol and other CNS depressants while on clorazepate therapy.
  
 - If a woman becomes pregnant during therapy or intends to become pregnant, communicate with physician about the desirability 
 of discontinuing the drug.